On August 28, Tempus AI fell 5.3% in regular trading, trading at $66.295/share, with turnover of $219 million. The decline was driven by CEO and Chairman Eric Lefkofsky's continued large-scale share disposals coupled with concentrated bearish positioning in the options market.

According to SEC filings, Lefkofsky plans to sell 250,000 shares of Class A common stock worth approximately $16.5 million through J.P. Morgan Securities, under a 10b5-1 trading plan adopted in March. This follows a prior sale of approximately 249,000 shares in late July at $40.79-$43.13 per share. On August 26, the options market saw a $1.06 million far-dated out-of-the-money call sold and $161,000 in OTM puts purchased, signaling institutional skepticism toward upside potential and hedging against downside risk.

The stock had risen over 5% on August 25 after FDA 510(k) clearance of its Tempus ECG-PH device for AI-enabled pulmonary hypertension detection. However, persistent insider selling and derivatives market bearish signals have offset the positive regulatory catalyst and weighed on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)